Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mosaic ImmunoEngineeringCPMV +11.11% Buyback Yield % is 0.00 as of Aug. 01, 2026. The stock has 2 warning signs investors should review. Among 735 Biotechnology companies, Mosaic ImmunoEngineering ranks worse than 136054.29% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPMV vs TCRT, JAGX, BGMS: Buyback Yield % Comparison
For the Biotechnology subindustry, Mosaic ImmunoEngineering's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mosaic ImmunoEngineering Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mosaic ImmunoEngineering's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Mosaic ImmunoEngineering's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mosaic ImmunoEngineering (CPMV) has a Buyback Yield % of 0.00 as of Aug. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Mosaic ImmunoEngineering and its competitors. According to the industry distribution chart, Mosaic ImmunoEngineering ranks #999999 out of 735 companies in the Biotechnology industry.
Is Mosaic ImmunoEngineering's Buyback Yield % too high?
Mosaic ImmunoEngineering's current Buyback Yield % is 0.00. Based on the distribution chart, Mosaic ImmunoEngineering ranks #999999 out of 735 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Mosaic ImmunoEngineering's Buyback Yield % compare to TCRT and JAGX?
According to the Biotechnology industry distribution chart, Mosaic ImmunoEngineering ranks #999999 out of 735 companies for Buyback Yield %. This places Mosaic ImmunoEngineering in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Mosaic ImmunoEngineering and its competitors. Mosaic ImmunoEngineering's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mosaic ImmunoEngineering stock overvalued right now?
Mosaic ImmunoEngineering (CPMV) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Mosaic ImmunoEngineering (CPMV), the current Buyback Yield % is 0.00 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. It has a single operating segment for the purposes of assessing performance and making operating decisions. The company is pursuing new product candidates and platforms to build a product pipeline based on its deep understanding of immunotherapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPMV has been successfully added to your 
